Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Spliceosome-Mutant Leukemia Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ZRSR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ZRSR2 Recombinant Protein (Full-length / CCCH Zinc Finger Domain) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spectrometry. Suitable for RNA-binding assays. |
View ZRSR2 Products |
| Gene Delivery | ZRSR2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and splicing reporter assays (WT and MDS-associated mutants). |
View ZRSR2 Products |
| Benchmark Ab | Anti-ZRSR2 Recombinant Antibody Recombinant positive control for western blot, IP, and intracellular flow cytometry. |
View ZRSR2 Products |
| Validator | ZRSR2 siRNA Set For knockdown verification in synthetic lethality screening. |
View ZRSR2 Products |
| Related Target A | SF3B1 Core component of the U2 snRNP. Highly mutated in MDS; primary target for synthetic lethality in ZRSR2-mutant backgrounds. |
View SF3B1 Products |
| Related Target B | U2AF1 U2 auxiliary factor 1. Works in tandem with ZRSR2 in 3' splice site recognition; critical for comparative spliceosome profiling. |
View U2AF1 Products |
| Related Target C | PRMT5 Protein arginine methyltransferase 5. Symmetrical dimethylation of Sm proteins regulates spliceosome assembly; highly synergistic target. |
View PRMT5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zinc Finger Oxidation & Instability | ZRSR2 proteins purified under strict reducing conditions with zinc supplementation to preserve native CCCH conformation. |
| Splicing Mutant Modeling | Premade Lentiviral particles expressing common clinical mutations (e.g., frameshift/nonsense mutations) for disease-state cell lines. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated siRNA sets included for target validation. |
| Nonspecific RNA Binding | High-purity, low-background recombinant ZRSR2 ensures high signal-to-noise ratio in electrophoretic mobility shift assays (EMSA). |
Live ZRSR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ZRSR2-targeted therapeutics is intensifying, with major players shifting focus from traditional gene overexpression to small-molecule spliceosome modulators and synthetic lethality strategies. As first-generation splicing inhibitors reach the clinic, the next wave of R&D is targeting the minor spliceosome pathway specifically to avoid systemic toxicity associated with major spliceosome inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Spliceosome Modulators | H3 Biomedicine, Syros Pharmaceuticals | MDS, AML, CMML | In vitro RNA-binding assays (Need high-purity recombinant ZRSR2) |
| Synthetic Lethal Inhibitors (PRMT5/SF3B1) | AstraZeneca, Prelude Therapeutics | Solid Tumors, Hematological Malignancies | Isogenic cell line generation (Need Lentiviruses for ZRSR2 WT/KO) |
| Antisense Oligonucleotides (ASOs) | Ionis Pharmaceuticals | Spliceosome-mutant Cancers | Splicing efficiency assays (Need ZRSR2-specific qPCR/Western controls) |